- Home
- CULP vs MREO Comparison
CULP vs MREO Comparison
Compare CULP & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CULP | MREO |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 50.3M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CULP | MREO |
|---|---|---|
| Price | $3.31 | $0.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 11.7K | ★ 4.9M |
| Earning Date | 03-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.06 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $203,482,000.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | $8.42 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.70 | $0.20 |
| 52 Week High | $4.75 | $2.37 |
Technical Indicators
Market Signals| Indicator | CULP | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 50.30 |
| Support Level | $3.07 | $0.28 |
| Resistance Level | $3.50 | $0.35 |
| Average True Range (ATR) | 0.14 | 0.03 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 29.04 | 42.12 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).